MAP4K2 anticorps (AA 386-469)

N° du produit ABIN7160065

Détail du produit anti-MAP4K2 anticorps

Antigène: MAP4K2 (Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2 (MAP4K2))

Épitope: AA 386-469

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp MAP4K2 est non-conjugé

Application: ELISA, Immunohistochemistry (IHC), Immunofluorescence (IF)

Réactivité croisée: Humain

Purification: >95%, Protein G purified

Immunogène: Recombinant Human Mitogen-activated protein kinase kinase kinase kinase 2 protein (386-469AA)

Isotype: IgG

Information d'application

Indications d'application: Recommended dilution: IHC:1:500-1:1000, IF:1:50-1:200,

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C,-80 °C

Stockage commentaire: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Détails sur MAP4K2

Antigène: MAP4K2 (Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2 (MAP4K2))

Autre désignation: MAP4K2 (MAP4K2 Produits)

Synonymes: anticorps BL44, anticorps GCK, anticorps RAB8IP, anticorps AI385662, anticorps Rab8ip, anticorps MAP4K2, anticorps dZ150L22.2, anticorps map4k2l, anticorps map4k2l-2, anticorps map4k3l, anticorps si:dz150l22.2, anticorps si:dz263j20.1, anticorps zgc:136670, anticorps mitogen-activated protein kinase kinase kinase kinase 2, anticorps mitogen activated protein kinase kinase kinase kinase 2, anticorps MAP4K2, anticorps Map4k2, anticorps LOC103346779, anticorps map4k2

Sujet:

Background: Serine/threonine-protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Acts as a MAPK kinase kinase kinase (MAP4K) and is an upstream activator of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway and to a lesser extent of the p38 MAPKs signaling pathway. Required for the efficient activation of JNKs by TRAF6-dependent stimuli, including pathogen-associated molecular patterns (PAMPs) such as polyinosine-polycytidine (poly(IC)), lipopolysaccharides (LPS), lipid A, peptidoglycan (PGN), or bacterial flagellin. To a lesser degree, IL-1 and engagement of CD40 also stimulate MAP4K2-mediated JNKs activation. The requirement for MAP4K2/GCK is most pronounced for LPS signaling, and extends to LPS stimulation of c-Jun phosphorylation and induction of IL-8. Enhances MAP3K1 oligomerization, which may relieve N-terminal mediated MAP3K1 autoinhibition and lead to activation following autophosphorylation. Mediates also the SAP/JNK signaling pathway and the p38 MAPKs signaling pathway through activation of the MAP3Ks MAP3K10/MLK2 and MAP3K11/MLK3. May play a role in the regulation of vesicle targeting or fusion. regulation of vesicle targeting or fusion.

Aliases: B lymphocyte serine/threonine protein kinase antibody, B lymphocyte serine/threonine-protein kinase antibody, BL44 antibody, GC kinase antibody, GCK antibody, Germinal center kinase antibody, germinal centre kinase (GC kinase) antibody, M4K2_HUMAN antibody, Map4k2 antibody, MAPK/ERK kinase kinase kinase 2 antibody, MEK kinase kinase 2 antibody, MEKKK 2 antibody, Mitogen activated protein kinase kinase kinase kinase 2 antibody, Mitogen-activated protein kinase kinase kinase kinase 2 antibody, Rab8 interacting protein antibody, Rab8 interacting protein, formerly antibody, Rab8-interacting protein antibody, RAB8IP antibody, RAB8IP, formerly antibody

UniProt: Q12851